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Abstract
Background: Despite extensive research, the details of the biological mechanisms by which cancer cells acquire
motility and invasiveness are largely unknown. This study identifies an invasion associated gene signature shedding
light on these mechanisms.
Methods: We analyze data from multiple cancers using a novel computational method identifying sets of genes
whose coordinated overexpression indicates the presence of a particular phenotype, in this case high-stage cancer.
Results: We conclude that there is one shared “core” metastasis-associated gene expression signature
corresponding to a specific variant of stromal desmoplastic reaction, present in a large subset of samples that have
exceeded a threshold of invasive transition specific to each cancer, indicating that the corresponding biological
mechanism is triggered at that point. For example this threshold is reached at stage IIIc in ovarian cancer and at
stage II in colorectal cancer. Therefore, its presence indicates that the corresponding stage has been reached. It has
several features, such as coordinated overexpression of particular collagens, mainly COL11A1 and other genes,
mainly THBS2 and INHBA. The composition of the overexpressed genes indicates invasion-facilitating altered
proteolysis in the extracellular matrix. The prominent presence in the signature of INHBA in all cancers strongly
suggests a biological mechanism centered on activin A induced TGF-b signaling, because activin A is a member of
the TGF-b superfamily consisting of an INHBA homodimer. Furthermore, we establish that the signature is
predictive of neoadjuvant therapy response in at least one breast cancer data set.
Conclusions: Therefore, these results can be used for developing high specificity biomarkers sensing cancer
invasion and predicting response to neoadjuvant therapy, as well as potential multi-cancer metastasis inhibiting
therapeutics targeting the corresponding biological mechanism.
Background
There is currently great interest in identifying the biolo-
gical mechanisms for the acquisition of motility and inva-
siveness in cancer. It has been hypothesized [1,2] that
they often involve some form of epithelial-mesenchymal
transition (EMT), significant involvement of the tumor
microenvironment [3,4] and the presence of activated
fibroblasts in the “reactive” desmoplastic stroma of
tumors, referred to as “cancer associated fibroblasts”
(CAFs) [5,6].
A study [7] of serous papillary ovarian carcinomas,
comparing the gene expression profiles of primary vs.
omental metastatic tumors, identified 156 differentially
expressed genes. To investigate the significance of these
genes in an independent rich data set we performed
hierarchical clustering, using only these genes, on The
Cancer Genome Atlas (TCGA) gene expression data set
consisting of 377 ovarian cancer samples containing sta-
ging information. The resulting heat map revealed a
prominent block of about 100 highly overexpressed
genes in 94 samples (Additional file 1). Remarkably, we
found that none of the 41 samples from tumors of
stages IIIb and below were among the 94 samples. This
cannot be due to chance (p = 4 × 10
-6), leading to the
hypothesis that coordinated overexpression of these
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stage IIIc.
To further validate this hypothesis and test if similar
versions apply to other cancers, we developed a compu-
tational technique identifying in an unbiased manner
coordinatedly overexpressed genes associated with a
phenotype (such as transition to a particular stage). Our
results consistently rediscover the same “core” signature
of overexpressed genes, confirming the hypothesis. We
found that the signature is present in multiple cancers,
each of which has its own features involving additional
genes, but the core signature is common.
As evidenced by the presence of FAP (fibroblast activa-
tion protein) and ACTA2 (actin, alpha 2, also known as
a-SMA, alpha-smooth muscle actin) in the set of overex-
pressed genes, the signature suggests a variant of stromal
desmoplastic reaction. As further evidence, it is known
([6], p. 546) that activated fibroblasts (myofibroblasts) con-
struct the desmoplastic stroma through the secretion of
large amounts of collagen, fibronectin (FN1) and proteo-
glycans, and they secrete various proteases such as uroki-
nase plasminogen activator (PLAU) and matrix
metalloproteinases (MMPs). This list precisely describes
most of the genes appearing in the signature, and its pre-
cise composition (e.g., having COL11A1 as the prominent
collagen, MMP11 as the prominent metalloproteinase, and
CDH11 as the prominent cadherin) points to a particular
variant of CAFs, to which we refer as “metastasis asso-
ciated fibroblasts” (MAFs). Indeed, the resulting proteoly-
tic remodeling at the invasive edge of the tumor is
thought to facilitate the initial invasive stage of the meta-
static process by “excavating passageways” ([6], p. 621)
through the extracellular matrix for the cancer cells to go
through. Accordingly, in the following we refer to the cor-
responding gene expression signature and biological
mechanism as “the MAF signature” and “the MAF
mechanism,” respectively.
Methods
List of data sets
The list of data sets in the paper is given in Table 1. They
were identified by searching for rich data sets focused on
a specific cancer in two public databases, The Cancer
Genome Atlas and the Gene Expression Omnibus data
depository. Furthermore, for the data sets initially used to
infer the gene signature we required that they have well
annotated staging information associated with the sam-
ples and that they contain a significant number of sam-
ples in both lower and higher stages so that we could
compare the expression profiles across stages.
Extreme Value Association (EVA)
Since we aim to discover a set of genes that are coordi-
nately overexpressed only in a subset of the “high stage”
samples, we developed a special measure of association
b e t w e e nt h eg e n ea n dt h eb i n a r y( “high stage” vs. “low
stage”) phenotype that naturally fits this description,
ignoring the expression levels of the genes outside the
region of overexpression, which we call “extreme value
association” (EVA). The same measure can identify
coordinately silenced genes, but we did not find any
such genes across various cancer types.
The EVA metric is the minimum p-value of biased
partitions over all subsets of samples with highest
expression values of the gene. In other words, suppose
that there are totally M samples, out of which N are
“low stage” and M - N are “high stage,” and we select
the m samples with the highest gene expression values,
out of which n are “low stage” and m - n are “high
stage.” Under the assumption that gene expression
values are uncorrelated with the phenotype, the prob-
ability that there will be at most n “low stage” samples
among the selected m samples is given by the cumula-
tive hypergeometric probability h(x ≤ n; M, N, m). The
EVA metric is then defined as equal to -log10 of the
minimum of these probabilities over all possible choices
of m,i nw h i c hm ranges from 1 to M (note that
n depends on m). For example, assume that there are
250 high-stage samples and 50 low-stage samples for a
total of 300 samples. Furthermore, assume that the 100
samples with the highest values of a particular gene con-
tain 99 high-stage samples and one low stage sample. In
that case, h(x ≤ 1;300,50,100) can be evaluated using the
MATLAB function hypercdf (1,300,50,100) = 5 × 10
-9,
resulting in the EVA metric for that gene of at least
-log10(5 × 10
-9) = 8.3. If the 101
th sample is also high-
stage, then the EVA metric of the gene will be even
higher. Note that, once the highest value is reached, the
sorting arrangement of the remaining samples is irrele-
vant, reflecting the hypothesis that only the extreme
values are associated with the phenotype. Figure 1
shows the values of the cumulative hypergeometric
probability for the COL11A1 gene using the TCGA
ovarian cancer data set and the staging threshold for the
definition of the binary phenotype set between IIIb and
IIIc. The maximum (8.31) occurs when m = 133.
We then developed a mechanistic and unbiased (only
dependent on the phenotype) algorithm, which, when
given a gene expression data set for a number of sam-
ples labeled “high stage” or “low stage,” leads to a selec-
tion of genes that are coordinatedly overexpressed only
in high-stage samples, ignoring the effect of the rest,
thus precisely reflecting the observed phenomenon. We
first select the top 100 genes that rank highest according
to the EVA metric criterion using a mixture analysis
(selecting the minimum p-value) of both overexpressed
and silenced genes. Using this set of genes only, we per-
form k-means clustering with gap statistic [8]. At that
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they will align well in the heat map. This leads to the
selection of the samples belonging to the cluster most
associated with the high/low stage phenotype - call this
the set of “EVA-based samples.” N e x t ,w ed e f i n ea
“clean” MAF phenotype, contrasting the samples that
are: (a) both “EVA based” and “high-stage” against (b)
the samples that are both “non EVA-based” and “low
stage.” If the number of samples is sufficiently large, this
“clean” phenotype provides the sharpest way by which
we can identify the genes that are most associated with
the observed phenomenon of metastasis-associated
coordinated overexpression. We then rank the genes
and compute their multiple-test-corrected p-values
Table 1 Lists of Data sets in the paper
Data set name Source Site GEO Accession Affymetrix platform Sample size
TCGA Ovarian Cancer The Cancer Genome Atlas HT_HG-U133A
a 377
CCR Ovarian Cancer Gene Expression Omnibus GSE9891 HG-U133_Plus_2
b 285
CCR Colon Cancer Gene Expression Omnibus GSE14333 HG-U133_Plus_2 290
Moffitt Colon Cancer Gene Expression Omnibus GSE17536 HG-U133_Plus_2 177
Singapore Gastric Cancer Gene Expression Omnibus GSE15459 HG-U133_Plus_2 200
CCR Breast Cancer Gene Expression Omnibus GSE7390 HG-U133A
c 198
Wang Breast Cancer Gene Expression Omnibus GSE2034 HG-U133A 286
Samsung Lung Cancer Gene Expression Omnibus GSE8894 HG-U133_Plus_2 138
Bild Lung Cancer Gene Expression Omnibus GSE3141 HG-U133_Plus_2 111
Neuroblastoma tumor Gene Expression Omnibus GSE3960 HG_U95Av2 102
Neoadjuvant Breast Cancer Gene Expression Omnibus GSE4779 U133_X3P [65] 102
e
Postmortem - normal Gene Expression Omnibus GSE3526 HG-U133_Plus_2 353
Human body index - normal Gene Expression Omnibus GSE7307 HG-U133_Plus_2 504 [677]
f
aAffymetrix HT Human Genome U133A Array.
bAffymetrix Human Genome U133 Plus 2.0.
cAffymetrix Human Genome U133A.
d270 out of 341 samples are tumor samples.
e65 out of 102 are ER-negative samples.
f504 out of 677 samples are normal samples.
Figure 1 Evaluation of the EVA metric for gene COL11A1 in the TCGA ovarian cancer data set.
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phenotype and select the genes for which p < 10
-3 after
Bonferroni correction. Finally, we find the intersection
of these selected gene sets over all cancer expression
data sets and rank them in terms of fold change.
For a data set with n samples and m genes, the EVA
algorithm computes cumulative hypergeometric distri-
bution probabilities nm times. This can be computation-
ally intensive, so we devised a low-complexity
implementation algorithm described in Additional file 2.
Mutual Information and Synergy
Assuming that two variables, such as the expression
levels of two genes G1 and G2, are governed by a joint
probability density p12 with corresponding marginals p1
and p2 and using simplified notation, the mutual infor-
mation I(G1 ; G2) is a general measure of correlation
and is defined as the expected value E
p
pp
log 12
12
⎧
⎨
⎩
⎫
⎬
⎭
. The
synergy of two variables G1, G2, with respect to a third
variable G3 is [9] equal to I(G1, G2; G3)-[ I(G1; G3)+
I(G2; G3)], i.e., the part of the association of the pair G1,
G2 with G3 that is purely due to a synergistic coopera-
tion between G1 and G2 (the “whole” minus the sum of
the “parts”). We used a 3
rd order B-spline-based mutual
information estimator dividing the observation space
into six equally spaced bins in each dimension.
P-value estimation for mutual information and synergy
We applied a permutation-based approach accounting
for multiple test correction: We did 100 permutation
experiments of the class labels, saving the corresponding
100 highest values after doing exhaustive search in each
permutation experiment. Using the set of these 100
highest value scores, we obtained the maximum likeli-
hood estimates of the location parameter and the scale
parameter of the Gumbel (type-I extreme value) distri-
bution, resulting in a cumulative density function F. The
p-value of an actual score x0 is then 1 - F(x0)u n d e rt h e
null hypothesis of no association with phenotype. Simi-
larly, for the synergistic pair, we found the top-scoring
synergy in 100 data sets that were identical to the origi-
nal except that the phenotype values were randomly
permuted on each, and the top permuted synergy scores
were modeled, as above, with the Gumbel distribution.
Results
Identification of MAF signature genes from staging
information in four data sets
We performed the EVA algorithm on four rich gene
expression data sets, two from ovarian cancer, the one
from TCGA and another one [10], and two from color-
ectal cancer [11,12] accompanied by staging
information. We performedt h ea l g o r i t h mm u l t i p l e
times using the different possible cutoff thresholds
defining the phenotype, finding that, in all cases, it is
defined as exceeding stage IIIb in each of the ovarian
data sets and stage I in each of the colorectal data sets.
Interestingly, several among the “metastasis-associated
genes” identified in [7] as present in omental metastasis
of ovarian cancer were also identified in [10] as belong-
ing to a subtype of ovarian cancer characterized by
extensive desmoplasia, which contains the MAF
signature.
Remarkably, we found that there were 137 genes (listed
in Additional file 3), each of which had Bonferroni-cor-
rected p < 10
-3 in all four data sets. Table 2 shows a list
of these genes with average log fold change greater than
2. The top ranked gene was COL11A1 (probe 37892_at).
Again, these genes were found purely as a result of their
association with the staging phenotype in all four cancers.
Gene Ontology enrichment testing of these genes identi-
fied cell adhesion, extracellular matrix and collagen fibril
organization. It turns out that use of other standard cor-
relation measures instead of the EVA measure in the
same algorithms leads to the same results, because the
overall correlation of these genes with the phenotype is
strong merely as a result of the genes’ overexpression in
some high-stage samples alone. The EVA method has the
additional advantage of providing an estimate of the size
of that subset of high-stage samples.
We then did an extensive literature search aimed at
identifying other studies in which at least some of these
genes were identified as differentially expressed in var-
ious stages of other cancers. We even scrutinized studies
in which none of the genes were mentioned in the main
t e x t ,b yl o o k i n ga tt h e i rs u p p l e m e n t a r yd a t aa n dr e -
ranking particular columns of genes in terms of their
fold changes, from genes containing numerous genes.
Although most of our results were negative, we were
able to produce cancer gene lists with striking similarity
(Table 3) to our own list (Table 2) in three studies of
breast [13], gastric [14] and pancreatic [15] cancer.
Specifically, a breast cancer study [13] comparing duc-
tal carcinomas in situ (DCIS) with invasive ductal carci-
noma (IDC) had a list of genes upregulated in IDC that
had similarities to those we had identified, and the top-
ranked gene was again COL11A1 (probe 37892_at) with
log fold change of 6.50, while the next highest (4.08)
corresponded to another probe of COL11A1, followed
by a probe of COL10A1. Second, a study [14] comparing
early gastric cancer (EGC) with advanced gastric cancer
(AGC) - roughly separating stages I and II - also identi-
fied a similar differentially expressed gene list of which
again COL11A1 (probe 37892_at) was at the top (log
fold change: 4.26) followed by COL10A1 and FAP.
Third, a study of pancreatic ductal adenocarcinoma [15]
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tissue versus normal pancreatic tissue, in which
COL11A1 (probe 37892_at) is again prominent and the
top entry (log fold change 5.15) was INHBA, supportive
of our hypothesis of activin A induced TGF-b signaling.
The presence of the MAF signature in the latter study
indicates that pancreatic cancer had already become
invasive in most cases before the biopsy. The prominent
desmoplastic reaction in pancreatic cancers (which con-
tains the MAF signature) has recently been increasingly
recognized as a “foe” [16] that could lead to new thera-
peutic strategies targeting stromal cells to inhibit cancer.
Finally, we realized that COL11A1 has been identified as
a potential metastasis-associated gene in other types of
cancer as well, such as in lung [17], and oral cavity [18],
suggesting that the MAF signature may be present in a
subset of high stage samples of most if not all epithelial
cancers.
Using COL11A1 as proxy for the MAF signature in the
absence of staging information
In those cases as well as in our own findings, there was pro-
minent presence of COL11A1 (probe 37892_at). This
remarkable consistent strong association of COL11A1 with
the staging phenotype (specific to each cancer type) sug-
gests that it could be used as a “proxy” of the MAF signa-
ture. This would allow us to improve on the gene list of
Table 2 by making use of numerous publicly available gene
expression data sets of cancers of many types, even without
any staging information, as long as the MAF signature is
present in a sizeable subset of them, aiming at finding the
“intersection” of the associated factors in these sets, reveal-
ing the “core” of the MAF biological mechanism.
As a first step for this task, we identified the genes
that are consistently highest associated with COL11A1.
Additional file 4 shows a listing of genes in nine cancer
data sets, while Table 4 shows an aggregate list of the
top 100 genes ranked in terms of their association
(mutual information) with COL11A1. The list is similar
to the phenotype-based gene ranking (Table 2). In addi-
t i o nt oaf e wc o l l a g e n so ft y p eX I ,X ,V ,a n dI ,t h et o p
ranked genes are thrombospondin-2 (THBS2), inhibin
beta A (INHBA), leucine rich repeat containing 15
(LRRC15), versican (VCAN), fibroblast activation protein
(FAP), and matrix metallopeptidase 11 (MMP11)a k a
stromelysin 3. The presence of FAP indicates a general
desmoplastic reaction and is not, by itself, sufficient for
inferring the MAF signature.
Furthermore, contrary to all other genes, COL11A1 was
uniquely not associated with any of these genes in non-
cancerous samples, further supporting the hypothesis
that it can be used as a proxy for the MAF signature. Our
results indicate that THBS2 and INHBA, top ranked in
Table 4 except for collagens, are the most important
players in the MAF mechanism. Figure 2 demonstrates
this striking coexpression in data sets of cancer samples,
but not in noncancerous samples, in the form of scatter
plots. We have consistently validated this behavior in the
cancerous and noncancerous data sets we tested.
As a second step, we identified gene pairs that are
highest associated with COL11A1 jointly, but not indivi-
dually, and therefore they would not appear in the pre-
vious list. For this task we ranked gene pairs according
to their synergy [9] with COL11A1,u s i n gt h e
Table 2 Top-ranked genes associated with carcinoma
stage in four ovarian and colorectal cancers
Probe Set
a Gene Log FC
37892_at COL11A1 3.94
217428_s_at COL10A1 3.55
204320_at COL11A1 3.39
210809_s_at POSTN 3.14
206439_at EPYC 3.12
219087_at ASPN 2.99
205941_s_at COL10A1 2.88
203083_at THBS2 2.81
209955_s_at FAP 2.73
215446_s_at LOX 2.63
204051_s_at SFRP4 2.53
210511_s_at INHBA 2.52
215646_s_at VCAN 2.50
218469_at GREM1 2.48
209758_s_at MFAP5 2.42
218468_s_at GREM1 2.35
212353_at SULF1 2.34
221730_at COL5A2 2.34
211571_s_at VCAN 2.33
204619_s_at VCAN 2.33
205713_s_at COMP 2.31
221731_x_at VCAN 2.27
204620_s_at VCAN 2.26
201150_s_at TIMP3 2.25
221729_at COL5A2 2.24
212354_at SULF1 2.23
212489_at COL5A1 2.22
213790_at ADAM12 2.21
212488_at COL5A1 2.20
201147_s_at TIMP3 2.19
204457_s_at GAS1 2.17
206026_s_at TNFAIP6 2.14
202952_s_at ADAM12 2.12
202766_s_at FBN1 2.08
212344_at SULF1 2.07
202311_s_at COL1A1 2.05
209335_at DCN 2.01
aAffymetrix probe sets.
All genes have Bonferroni corrected p < 10
-3 in each of the four data sets.
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Page 5 of 11computational method in [19], which could further facil-
itate biological discovery. For example, the scatter plots
in Figure 3 show that genes ECM2 and TCF21 are
jointly, but not individually, strongly associated with
COL11A1 (p < 10
-6, see Methods) in the two ovarian
cancer data sets. Such findings are useful for developing
biological hypotheses, e.g. in this particular case they
suggest that in ovarian cancer the extracellular matrix
protein 2 is associated with the MAF signature only
when the TCF21 gene (a known mesenchymal-epithelial
transition mediator) is downregulated.
The MAF signature exists even in non-epithelial can-
cers. Indeed, we confirmed that neuroblastoma also car-
ries the MAF signature consistently associated with high
stage: As shown in Additional file 5, none of 21 stage I
samples have the signature (p = 4 × 10
-4), based on the
genes highest associated with COL11A1.
MicroRNAs and Methylated sites
We only had miRNA and methylation data available for
the TCGA ovarian data set. Using as measure the
mutual information with COL11A1, we found many
Table 3 Gene lists produced from information provided in the corresponding papers for other cancers
Breast Cancer, Shuetz et al
a Gastric cancer, Vecchi et al
b Pancreatic cancer, Badea et al
c
Probe Set
d Gene Symbol Log FC Probe Set
d Gene Symbol Log FC Probe Set
d Gene Symbol Log FC
37892_at COL11A1 6.50 37892_at COL11A1 4.26 227140_at INHBA 5.15
204320_at COL11A1 4.08 217428_s_at COL10A1 4.15 217428_s_at COL10A1 5.00
217428_s_at COL10A1 4.07 209955_s_at FAP 3.40 1555778_a_at POSTN 4.92
213764_s_at MFAP5 3.73 235458_at HAVCR2 3.30 212353_at SULF1 4.63
213909_at LRRC15 3.61 204320_at COL11A1 3.28 226237_at COL8A1 4.60
205941_s_at COL10A1 3.52 205941_s_at COL10A1 3.21 37892_at COL11A1 4.40
210511_s_at INHBA 3.44 204052_s_at SFRP4 2.90 225681_at CTHRC1 4.38
202766_s_at FBN1 3.43 226930_at FNDC1 2.85 202311_s_at COL1A1 4.12
212353_at SULF1 3.35 227140_at INHBA 2.77 203083_at THBS2 3.97
218468_s_at GREM1 3.35 209875_s_at SPP1 2.77 227566_at HNT 3.90
215446_s_at LOX 3.22 205422_s_at ITGBL1 2.63 204619_s_at CSPG2 3.87
221730_at COL5A2 3.22 226311_at — 2.63 229802_at WISP1 3.80
218469_at GREM1 3.20 222288_at — 2.62 212464_s_at FN1 3.69
212489_at COL5A1 3.08 231993_at — 2.50 205713_s_at COMP 3.53
203083_at THBS2 2.99 226237_at COL8A1 2.48 221729_at COL5A2 3.38
201505_at LAMB1 2.97 223122_s_at SFRP2 2.47 209955_s_at FAP 3.37
209955_s_at FAP 2.96 210511_s_at INHBA 2.43 229218_at COL1A2 3.16
209758_s_at MFAP5 2.92 203819_s_at IMP-3 2.39 209016_s_at KRT7 3.13
202363_at SPOCK 2.91 212464_s_at FN1 2.36 210004_at OLR1 3.03
213241_at NY-REN-58 2.90 212353_at SULF1 2.35 219773_at NOX4 3.02
205479_s_at PLAU 2.89 227995_at — 2.34 218804_at TMEM16A 2.90
206584_at LY96 2.88 225681_at CTHRC1 2.30 238617_at — 2.87
204475_at MMP1 2.83 204457_s_at GAS1 2.27 224694_at ANTXR1 2.82
202952_s_at ADAM12 2.83 216442_x_at FN1 2.25 228481_at COX7A1 2.77
201792_at AEBP1 2.81 223121_s_at SFRP2 2.23 226311_at ADAMTS2 2.76
204114_at NID2 2.81 211719_x_at FN1 2.23 201792_at AEBP1 2.68
213790_at ADAM12 2.80 204776_at THBS4 2.18 203021_at SLPI 2.65
209156_s_at COL6A2 2.77 210495_x_at FN1 2.15 227314_at ITGA2 2.58
219179_at DACT1 2.74 202800_at SLC1A3 2.13 205499_at SRPX2 2.44
212488_at COL5A1 2.73 214927_at — 2.11 226997_at — 2.41
219087_at ASPN 2.73 212354_at SULF1 2.09 219179_at DACT1 2.36
204619_s_at CSPG2 2.70 238654_at LOC147645 2.06 203570_at LOXL1 2.30
204337_at RGS4 2.69 213943_at TWIST1 2.06 201850_at CAPG 2.25
204620_s_at CSPG2 2.69 236028_at IBSP 2.05 222449_at TMEPAI 2.19
212354_at SULF1 2.68 228481_at POSTN 2.00 227276_at PLXDC2 2.16
aBreast cancer list indicates genes overexpressed in invasive ductal carcinoma vs. ductal carcinoma in situ.
bGastric cancer list indicates genes overexpressed in early gastric cancer vs. advanced gastric cancer.
cPancreatic cancer list indicates genes overexpressed in pancreatic ductal adenocarcinoma vs. normal pancreatic tissue.
dAffymetrix probe sets.
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22 and hsa-miR-152, as well as differentially methylated
genes, such as SNAI1 and PRAME, suggesting a particu-
larly complex biological mechanism (correlation with
the MAF phenotype led to essentially the same lists
with lower significance). Table 5 contains a list of the
miRNAs, while Table 6 contains a list of the methylated
genes (multiple test corrected p < 10
-16 in both cases,
see Methods). SNAI1 (snail) methylation is particularly
important as the gene is known as one of the most
important EMT-related transcription factors. Instead,
the strongest MAF-associated transcription factor is
AEBP1. Many of the other EMT-related transcription
factors, such as SNAI2, TWIST1, and ZEB1 are often
overexpressed in the MAF signature, but SNAI1 is not
(and, at least in ovarian carcinoma in which we have
methylation data, this is due to its differentially methy-
lated status). We believe that the lack of SNAI1 expres-
sion is a key distinguishing feature of the MAF
signature, in which we observed neither SNAI1 overex-
pression nor CDH1 (E-cadherin) downregulation, at
least on the mRNA level.
Drug response
Significantly, we also found that, at least in ER negative
breast cancer, the MAF signature is associated with
resistance to neoadjuvant FEC. This was demonstrated
in [20] where a stromal “metagene” signature of 50
genes was defined based on DCN (decorin). Although
some of the MAF key genes (such as COL11A1 and
THBS2) were not among these 50, the metagene signa-
ture used in that study has a significant intersection
with the MAF signature and was found resistant to
neoadjuvant chemotherapy. To compare the drug
response performance of the DCN metagene set with
that of the MAF signature, we used the top 50 genes
of the MAF signature in terms of their association
with COL11A1 from various cancers (the top genes
shown in Table 4) in the same data set. Shown in
Additional file 6 and Additional file 7 are two cluster-
ing heat maps of expression profiles, one with the
MAF signature genes and one with the DCN metagene
set, respectively. High expression of the MAF signature
genes correlates with lack of response to therapy (iden-
tifying 14 samples out of which 12 have lack of
response) more than high expression of the DCN
metagene set (identifying 12 samples out of which 10
have lack of response), suggesting that the presence of
t h ec o r eg e n e so ft h eM A Fs i g n a t u r ep r o v i d ea tl e a s t
as good indicator of resistance to neoadjuvant che-
motherapy. The reason for the drug resistance may
simply be that the invasiveness sensed by the MAF sig-
nature does not allow the size or extent of the cancer
to be reduced prior to surgery.
Table 4 Aggregate list of top genes associated with
COL11A1
Probe Set
a Gene MI
37892_at COL11A1 0.727 218469_at GREM1 0.231
204320_at COL11A1 0.640 201261_x_at BGN 0.228
203083_at THBS2 0.418 213125_at OLFML2B 0.228
217428_s_at COL10A1 0.386 201744_s_at LUM 0.228
205941_s_at COL10A1 0.373 202998_s_at ENTPD4 0.223
221729_at COL5A2 0.370 201438_at COL6A3 0.223
210511_s_at INHBA 0.368 212344_at SULF1 0.222
221730_at COL5A2 0.367 209596_at MXRA5 0.221
213909_at LRRC15 0.342 213764_s_at MFAP5 0.221
212488_at COL5A1 0.337 204589_at NUAK1 0.216
204619_s_at VCAN 0.326 217762_s_at RAB31 0.216
209955_s_at FAP 0.323 213905_x_at BGN 0.214
202311_s_at COL1A1 0.322 201150_s_at TIMP3 0.214
221731_x_at VCAN 0.320 221541_at CRISPLD2 0.214
203878_s_at MMP11 0.319 217763_s_at RAB31 0.212
212489_at COL5A1 0.318 217430_x_at COL1A1 0.212
210809_s_at POSTN 0.315 205422_s_at ITGBL1 0.210
202310_s_at COL1A1 0.314 201147_s_at TIMP3 0.209
204620_s_at VCAN 0.312 218468_s_at GREM1 0.209
202404_s_at COL1A2 0.304 217764_s_at RAB31 0.208
202952_s_at ADAM12 0.300 213765_at MFAP5 0.206
213790_at ADAM12 0.297 211668_s_at PLAU 0.203
203325_s_at COL5A1 0.296 207173_x_at CDH11 0.202
215076_s_at COL3A1 0.295 213338_at TMEM158 0.201
215446_s_at LOX 0.293 209758_s_at MFAP5 0.199
210495_x_at FN1 0.291 202363_at SPOCK1 0.195
201792_at AEBP1 0.291 201148_s_at TIMP3 0.195
216442_x_at FN1 0.286 204051_s_at SFRP4 0.193
212464_s_at FN1 0.286 207172_s_at CDH11 0.192
201852_x_at COL3A1 0.286 202283_at SERPINF1 0.191
212353_at SULF1 0.285 209335_at DCN 0.189
211719_x_at FN1 0.285 204298_s_at LOX 0.189
211161_s_at COL3A1 0.283 219655_at C7orf10 0.189
202403_s_at COL1A2 0.278 219561_at COPZ2 0.189
202766_s_at FBN1 0.272 219773_at NOX4 0.187
212354_at SULF1 0.266 204464_s_at EDNRA 0.186
219087_at ASPN 0.260 200974_at ACTA2 0.186
200665_s_at SPARC 0.258 202273_at PDGFRB 0.185
215646_s_at VCAN 0.257 61734_at RCN3 0.185
211571_s_at VCAN 0.256 213139_at SNAI2 0.183
202450_s_at CTSK 0.254 220988_s_at AMACR 0.182
206026_s_at TNFAIP6 0.253 205713_s_at COMP 0.181
202765_s_at FBN1 0.247 201105_at LGALS1 0.181
203876_s_at MMP11 0.240 213869_x_at THY1 0.180
212667_at SPARC 0.239 202465_at PCOLCE 0.174
222020_s_at HNT 0.239 208851_s_at THY1 0.174
206439_at EPYC 0.235 209156_s_at COL6A2 0.173
201069_at MMP2 0.234 221447_s_at GLT8D2 0.172
205479_s_at PLAU 0.234 204114_at NID2 0.171
206025_s_at TNFAIP6 0.232 205991_s_at PRRX1 0.171
aAffymetrix probe sets.
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A direct clinical application of these findings is the
development of a high-specificity invasion-sensing bio-
marker product detecting coordinated overexpression of
a few top-ranked genes, such as COL11A1, INHBA, and
THBS2, as shown in the scatter plots of Figure 2. A
positive result in seemingly low-stage primary tumors
will indicate that the disease has obtained the stromal
signature and thus has already reached an invasive stage.
As described above, the same product can also be used
to predict resistance to neoadjuvant chemotherapy.
Of course, the most significant clinical application
would be to develop metastasis-inhibiting therapeutics
using targets deduced from the biological knowledge pro-
v i d e db yt h eM A Fs i g n a t u r e .O u rt o pr a n k e dg e n e s
strongly suggest that they are produced by myofibroblasts
Figure 2 Scatter plots confirming coexpression of INHBA, THBS2, COL11A1 in cancerous but not healthy data sets. The expression of
COL11A1 is color-coded). As shown, COL11A1 is consistently coexpressed with INHBA and THBS2 in cancerous, but not in noncancerous samples,
two of which are shown on the right side.
Figure 3 Example of a synergistic pair of genes in two ovarian cancer data sets.
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Page 8 of 11or myofibroblast-like cells activated by activin A-induced
TGF-b signaling and leading to some form of altered pro-
teolysis [21], which results in extracellular matrix remo-
deling. Supporting this hypothesis are the facts that both
INHBA and THBS2 are involved in TGF-b signaling:
Activin A (INHBA homodimer) is a TGF-b superfamily
member (ligand) and THBS2 inhibits activation of TGF-
b by THBS1, which is also present in the MAF signature.
Remarkably, activin A is already known to facilitate fibro-
blast-mediated collagen gel contraction [22]. The role of
gene LRRC15 (aka LIB) appears important but unclear,
though it has already been recognized as promoting
migration through the extracellular matrix [23]. Versican
(VCAN) is an extracellular matrix proteoglycan already
known to play a role in metastasis, while MMP11 is one
of several matrix metalloproteinases involved in the
breakdown of extracellular matrix.
Although each of the MAF signature molecules could
serve as a potential therapeutic target, the hypothesis
that activin A signaling is at the heart of the MAF
mechanism immediately suggests that follistatin (activin-
binding protein) could serve as a metastasis inhibitor,
which is exactly what recent research [24] indicates.
Specifically, lung cancer cell lines transfected with follis-
tatin and injected into immunodeficient mice markedly
inhibited metastasis compared with non-transfected cell
lines, but the authors of the study recognize that the
role of follistatin in cancer metastasis is totally unknown
[25]. Our work provides an explanation and suggests
that the same could be true for other cancers as well.
Further support is provided by the fact that follistatin
virtually abolished the fibroblast-mediated collagen gel
contraction mentioned earlier [22].
T h e r ea r es e v e r a lr e a s o n st h a tt h ec o r eM A Fs i g n a -
ture has not yet been discovered as a multi-cancer
metastasis-associated signat u r e .F i r s t ,i ti se s s e n t i a lt o
identify the correct phenotypic staging threshold
recognizing that the signature only exists in a subset of
tumors that exceed that particular stage. Indeed, if the
threshold in breast cancer was put between stage I and
stage II, or between stage II and stage III, rather than
between in situ and stage I, the signature would not be
apparent. Second, each cancer type may have its own
additional features accompanying the MAF signature.
For example, in ovarian cancer it is accompanied by
sharp downregulation of genes COLEC11, PEG3 and
TSPAN8, which is not the case in other cancers.
Indeed, the main contribution of our work is the iden-
tification of the common multi-cancer “core” signature,
from which a universal metastasis-associated biological
mechanism can be identified. Third, the MAF signa-
ture may be reversible, perhaps as a result of the dis-
appearance of many of the stromal cells in the mature
desmoplastic stroma when it is replaced by “acellular”
matrix [6]. The presence of the signature in high-stage
samples may even paradoxically be associated with
longer survival if its reversal is required for further dis-
tant metastases (see below).
An important topic of further research is the deter-
mination of the precise biological event of interaction
of cancer cells with the microenvironment that gives
Table 5 Top-ranked miRNAs in MAF signature in the
TCGA ovarian cancer data set
miRNA MI Up/Down
Regulated
hsa-miR-22 0.204 Up
hsa-miR-514-1|hsa-miR-514-2|hsa-miR-514-3 0.193 Down
hsa-miR-152 0.187 Up
hsa-miR-508 0.168 Down
hsa-miR-509-1|hsa-miR-509-2|hsa-miR-509-3 0.164 Down
hsa-miR-507 0.152 Down
hsa-miR-509-1|hsa-miR-509-2 0.147 Down
hsa-miR-506 0.146 Down
hsa-miR-509-3 0.144 Down
hsa-miR-214 0.128 Up
hsa-miR-510 0.116 Down
hsa-miR-199a-1|hsa-miR-199a-2 0.115 Up
hsa-miR-21 0.112 Up
hsa-miR-513c 0.108 Down
hsa-miR-199b 0.103 Up
All miRNAs have multiple test corrected p < 10
-16 in terms of their association
with COL11A1.
Table 6 Top-ranked methylation sites in MAF signature
in the TCGA ovarian cancer data set
Methylation site MI Hyper-/Hypomethylated
PRAME 0.223 Hyper
SNAI1 0.183 Hyper
KRT7 0.158 Hyper
RASSF5 0.157 Hyper
FLJ14816 0.155 Hyper
PPL 0.155 Hyper
CXCR6 0.153 Hypo
SLC12A8 0.148 Hyper
NFATC2 0.148 Hyper
HOM-TES-103 0.147 Hypo
ZNF556 0.147 Hyper
OCIAD2 0.146 Hyper
APS 0.142 Hyper
MGC9712 0.139 Hyper
SLC1A2 0.136 Hyper
HAK 0.131 Hypo
C3orf18 0.13 Hyper
GMPR 0.13 Hyper
CORO6 0.128 Hyper
All methylated genes have multiple-test corrected p < 10
-16 in terms of their
association with COL11A1.
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siveness. Because of the recognized similarities with
the mechanisms of wound healing [26], it is likely that
this event uses existing wound healing response path-
ways. For example, it appears to occur very early in
breast cancer, late in ovarian cancer, and never in glio-
blastoma (which is reasonable, because glioblastoma
metastasizes extremely rarely). The late appearance of
the MAF signature in ovarian cancer and its presence
in omental metastases can be explained by the fact
that ovarian cancer initially progresses by disseminat-
ing locally across mesothelial surfaces and that, con-
trary to hematogenously metastasizing tumors, initial
metastasis is probably carried by the physiological
movement of peritoneal fluid to the peritoneum and
omentum [27].
Several of the top-ranked genes in the MAF signature
(such as thrombospondins, decorin, INHBA itself) are
known to be potent anti-angiogenesis mediators. The
reversal of the MAF signature would thus facilitate
further metastatic dissemination to distant sites. In
other words, (a) the desmoplastic MAF signature and
(b) angiogenesis, are two independent biological events.
The former appears to be based on activin A signaling,
as several of the MAF proteins in addition to INHBA
are also known inhibitors of the standard TGF-b ligand.
The reversal of the MAF signature would allow the
standard ligand to take over in TGF-b signaling, and
may thus facilitate further metastasis. These observa-
tions provide explanations for the seemingly contradic-
tory observed roles of TGF-b signaling inhibiting early
cancer but facilitating metastasis.
The possible reversibility of the MAF signature leads
to the intriguing hypothesis that perhaps all metastases
have, at some point temporarily been there, which
e x p l a i n sw h yw eo n l yo b s e r v ei ti nas u b s e to ft h e m .
This would be particularly exciting, because in that case
any metastasis-inhibiting therapeutic intervention target-
ing the MAF mechanism would be widely applicable to
low-stage tumors.
Conclusions
In conclusion, we have shown that, using purely computa-
tional analysis of publicly available biological information,
systems biology has revealed the core of a multi-cancer
metastasis-associated gene expression signature. In the
near future, a vast amount of additional information will
become available, including next generation sequencing,
miRNA and methylation information for many cancers,
which will allow additional computational research build-
ing on this work and clarifying the details of the underly-
ing invasion-associated complex biological process.
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